Clinical Trial Detail

NCT ID NCT01909453
Title Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Array BioPharma
Indications

melanoma

Therapies

Vemurafenib

Encorafenib

Binimetinib + Encorafenib

Age Groups: adult senior

Additional content available in CKB BOOST